(19)
(11) EP 1 529 047 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.05.2010 Bulletin 2010/20

(45) Mention of the grant of the patent:
21.02.2007 Bulletin 2007/08

(21) Application number: 03748238.7

(22) Date of filing: 13.08.2003
(51) International Patent Classification (IPC): 
C07D 473/00(2006.01)
(86) International application number:
PCT/GB2003/003554
(87) International publication number:
WO 2004/016612 (26.02.2004 Gazette 2004/09)

(54)

NEW PURINE DERIVATIVES

NEUE PURINE DERIVATE

NOUVEAUX DERIVES PURIQUES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GR HU IE IT LI LU MC NL PT RO SE SI SK TR

(30) Priority: 15.08.2002 GB 0219054

(43) Date of publication of application:
11.05.2005 Bulletin 2005/19

(73) Proprietors:
  • Cyclacel Limited
    London N1 7JQ (GB)
  • Cancer Research Technology Limited
    London WC2A 3NL (GB)

(72) Inventors:
  • FISCHER, Peter
    Arbroath, Angus DD11 2EN (GB)
  • JARMAN, Michael
    London SW17 7DY (GB)
  • MCDONALD, Edward
    Reigate, Surrey RH2 0LJ (GB)
  • NUTLEY, Bernard
    Sutton, Surrey SM1 4QT (GB)
  • RAYNAUD, Florence
    London SW20 8RF (GB)
  • WILSON, Stuart
    Sutton, Surrey SM2 5BY (GB)
  • WORKMAN, Paul
    Abinger Common, Surrey RH5 6JQ (GB)

(74) Representative: Clyde-Watson, Zöe et al
D Young & Co LLP 120 Holborn
London EC1N 2DY
London EC1N 2DY (GB)


(56) References cited: : 
WO-A-97/20842
WO-A-99/07705
US-A1- 2002 049 218
 WO-A-98/05335
WO-A-03/002565
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).